Furthermore, two glioma databases suggest patients with high DYRK3 expression have a median survival period that is roughly five times shorter than those with low DYRK3 expression (21.3 vs. 105.2 or 17.8 vs. 83.1 months, respectively. The gene discussed is DYRK3; the disease is glioma.